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Abstract
Background: During the last decade, pharmaceutical spending for patients with attention-deficit-hyperactivity
disorder (ADHD) has been escalating internationally.
Objectives: First, to estimate future trends of ADHD-related drug expenditures from the perspectives of the
statutory health insurance (SHI; Gesetzliche Krankenversicherung, GKV) in Germany and the National Health
Service (NHS) in England, respectively, for children and adolescents age 6 to 18 years. Second, to evaluate the
budgetary impact on individual prescribers (child and adolescent psychiatrists and pediatricians treating patients
with ADHD) in Germany.
Methods: A model was developed to predict plausible scenarios of future pharmaceutical expenditures for
treatment of ADHD. Model inputs were derived from demographic and epidemiological data, a literature review
of past spending trends, and an analysis of new pharmaceutical products in development for ADHD. Only
products in clinical development phase III or later were considered. Uncertainty was addressed by way of scenario
analysis. For each jurisdiction, five scenarios used different assumptions of future diagnosis prevalence, treatment
prevalence, rates of adoption and unit costs of novel drugs, and treatment intensity.
Results: Annual ADHD pharmacotherapy expenditures for children and adolescents will further increase and
may exceed €310 m (D; E: 78 m) in 2012 (2002: ~€21.8 m; ~7.0 m). During this period, overall drug spending by
individual physicians may increase 2.3- to 9.5-fold, resulting from the multiplicative effects of four variables:
increased number of diagnosed cases, growing acceptance and intensity of pharmacotherapy, and higher unit costs
of novel medications.
Discussion: Even for an extreme low case scenario, a more than six-fold increase of pharmaceutical spending
for children and adolescents is predicted over the decade from 2002 to 2012, from the perspectives of both the
NHS in England and the GKV in Germany. This budgetary impact projection represents a partial analysis only
because other expenditures are likely to rise as well, for instance those associated with physician services,
including diagnosis and psychosocial treatment. Further to this, by definition budgetary impact analyses have little
to nothing to say about clinical appropriateness and about value of money.
Conclusion: Providers of care for children and adolescents with ADHD should anticipate serious challenges
related to the cost-effectiveness of interventions.
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Background
In the United States, identification of attention-deficit/
hyperactivity disorder (ADHD) among children and ado-
lescents showed the greatest increase of all categories of
psychosocial problems [1], and the percentage of children
with a diagnosis of ADHD receiving medications
increased from 32% in 1979 to 78% in 1996 [1-3]. For the
mid-1990s, overall psychostimulant treatment prevalence
rates in children and adolescents were found at about
2.5% [4], ranging from 1.9% in a California health plan
[5] to 3.0% in national database analyses [6,7]. In the late
1990s, growth rates of stimulant prescriptions accelerated
in the United States [8,9]. For 1997, treatment prevalence
was reported at 4.1% (or 78% of children with ADHD)
[10]. In a survey of school nurses conducted in Baltimore,
Maryland, in 1998, 2.92% of all public school students
(N = 816,465) were administered a medication for ADHD
in school; 84% of those (2.46%) received methylpheni-
date [4]. In 1999, in a nationally representative, commer-
cially insured sample population 5 to 14 years old, the
one-year prevalence of stimulant treatment was 4.2 per-
cent in the United States [11]. According to another survey
conducted between 1997 and 1999 among parents of ele-
mentary school children in public elementary schools in
North Carolina, medication prevalence was even 7% in
the population studied, with stimulants accounting for
93% of the prescriptions [12]. More recent data have been
somewhat contradictory, with one analysis finding a treat-
ment prevalence of 4.8% in children (age 6–12 years) and
3.2% in adolescents (age 13–19 years), suggesting that the
steep increase of the late 1990s may have attenuated in
these age groups [13], whereas another study published
by Medco Health Solutions [14], a large U.S. pharmacy
benefit management organization, still found the number
of individuals age 19 years or younger using ADHD med-
ications increasing by 49% (males) and 82% (females)
between 2000 and 2004.
Meanwhile, the growth of pediatric psychotropic prescrip-
tions has become an international phenomenon [15]. For
stimulant treatment, similar trends as in the US – albeit at
lower absolute levels – have been observed in Canada
[16] and Europe. For instance, in Spain the consumption
of methylphenidate increased by 8% annually from 1992
to 2001 [17]. A study in six general practices in the Neth-
erlands showed a threefold rise of methylphenidate users
between 1998 and 2003 [18]. In England, the number of
methylphenidate prescriptions dispensed in the commu-
nity increased from 126,000 in 1998 to 389,200 in 2005
(or +207%; cf. Figure 1a), compared to a total growth of
prescriptions of +40% during the same period [19]. In
Germany, the number of defined daily doses (DDDs) of
methylphenidate prescribed for outpatients insured by
statutory sick funds ("Gesetzliche Krankenversicherung",
GKV, covering approximately 90% of the German
population) grew 47-fold between 1992 and 2005 [20],
while total prescriptions written in Germany decreased by
41% in the same period (cf. Figure 2).
Much of the debate triggered by this trend has focused on
medical aspects, such as concerns about potential overuse
of psychostimulants [21,22] and adverse treatment effects
[23]. It has, however, been argued that underuse may be
more of a problem, at least in Europe [24], and low rates
of recognition of ADHD or hyperkinetic disorder in the
United Kingdom were associated with insensitive diag-
nostic assessments [25]. Recent German methylphenidate
prescription analyses based on a regional sample of
11,235 children and adolescents with a diagnosis of
ADHD in Germany (year 2003) did not reveal overuse
[26]. Even for the United States, no evidence was found to
substantiate claims of abuse and inappropriate use of
methylphenidate [27], although there have been occa-
sional reports on diversion to peers of stimulant medica-
tions, especially short-acting formulations [28,29].
Beyond clinical implications, in an era of limited availa-
ble resources, the economic dimension associated with
increased health care utilization can no longer be ignored.
In economic terms, the opportunity cost of medical inter-
ventions will be approximated by their budgetary impact
– in particular, if a payers' perspective is adopted. Indeed,
budgetary impact analyses are requested by a growing
number of health care policy makers as an input into the
decision-making process about health care resource allo-
cation [30]. In practice, results of such analyses are fre-
quently interpreted with a notion of "affordability" in
mind. Unfortunately budget impact may exceed the pure
effects of increased treatment rates if, for instance, rates of
diagnosis (administrative prevalence), unit costs (for
instance owing to introduction of novel, usually more
expensive treatment options, which may be used in addi-
tion to or substituting cheaper alternatives), or treatment
intensity (in terms of dose or duration) change simultane-
ously. No doubt, all these factors come into play in ADHD
among children and adolescents. More than this, they
may interact with each other, reinforcing their combined
effects: for instance, availability of more expensive novel
medications will result in enhanced communication and
promotional efforts by their manufacturers, which in turn
will – in addition to their direct influence on physician
treatment choices (i.e., increase market share) – influence
awareness and identification of the disorder (i.e., increase
market size and aggregate number of prescriptions
[25,31,32]). Furthermore, recent results of long-term clin-
ical trials such as the landmark NIMH Multimodal Treat-
ment Study (MTA) have demonstrated the effectiveness,
in particular in terms of ADHD core symptom relief, of an
intense medication management strategy [33-38]), thusChild and Adolescent Psychiatry and Mental Health 2007, 1:13 http://www.capmh.com/content/1/1/13
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ADHD-related prescriptions and expenditures in England, 1998 – 2005 Figure 1
ADHD-related prescriptions and expenditures in England, 1998 – 2005. a: Prescription items dispensed in the com-
munity; b: Expenditures by category p.a.; DEX: dexamphetamine (DexedrineR and others); MPH: methylphenidate; IR: immedi-
ate-release formulations (RitalinR and generics); MR: modified-release formulations (ConcertaR XL, EquasymR XL; RitalinR SR 
imports); MOD: modafinil (ProvigilR, licensed for daytime sleepiness); ATX: atomoxetine (StratteraR); PEM: pemoline (VolitalR, 
before 2002 only, not shown due to small volume); data source: NHS Prescription Cost Analysis 1999–2006 [19]. Note that 
these data include prescriptions for adults with ADHD and also for other indications (narcolepsy).
Rx Items Dispensed 1998-2005
0
100,000
200,000
300,000
400,000
500,000
600,000
12345678
ATX
MOD
MPH-MR
MPH-IR
DEX
a
98 99 00 01 02 03 04 05
Rx Expenditures 1998-2005
£0
£5,000,000
£10,000,000
£15,000,000
£20,000,000
£25,000,000
12345678
ATX
MOD
MPH-MR
MPH-IR
DEX
98 99 00 01 02 03 04 05
bChild and Adolescent Psychiatry and Mental Health 2007, 1:13 http://www.capmh.com/content/1/1/13
Page 4 of 17
(page number not for citation purposes)
contributing to the increasing acceptance and intensity of
pharmacotherapy.
With the introduction of new products commanding
higher units costs (cf. Table 1), growth of pharmaceutical
spending has outpaced the rising number of prescriptions.
In the United States, prescription drug expenditures for
ADHD in children increased by 183% between 2000 and
2003. By 2003, spending on behavioral medications to
treat children had overtaken both the antibiotic and
asthma segments, which are traditionally high-use catego-
ries in pediatric medicine [39]. According to IMS
data, total U.S. sales of ADHD drugs reportedly rose from
US-$759 million in 2000 to US-$3.1 billion in 2004 [40].
Analysts from Merrill Lynch expect the U.S. ADHD market
(including adult patients) to exceed US-$4 billion by
2010 on the back of new products (cf. below, Table 2[41]).
In Germany, total GKV outpatient spending for psychos-
timulants rose from  1.25 m in 1995 to  23.7 m in 2002
(before the first modified-release product had been
launched) and  51.6 million in 2004 [20], 56% of which
were accounted for by MPH-MR12. Spending for ADHD
medications reached  82 million in 2005, exceeding our
earlier forecasts, which had predicted annual expenditures
of approximately  108 million (range from  62 to  155
million) by 2009 [42,43]. Apart from the launch of atom-
oxetine in March 2005, this substantial increase was pri-
marily driven by spending for two modified-release
preparations of methylphenidate (cf. Table 1), both of
which ranked among the top-100 products in terms of
sales [44].
In England spending for ADHD-related pharmacother-
apy, including modafinil and atomoxetine, increased
from 1998 (3.1 million) to 2005 (24.4 million) by
+695% (Figure 1b), again exceeding the growth of pre-
scriptions (for ADHD treatments between 1998 and 2005,
+132%)[19]. One new product (MPH-MR12, cf. Table 1)
alone accounted for 42% of prescriptions, and 45% of
pharmaceutical expenditures, for ADHD in 2005 [19].
Average costs per prescription rose steadily from 13.68 in
1998 to 46.94 in 2005, driven by price increases for dex-
amphetamine and a shift to more expensive new prod-
ucts: Combined, all new products with once-daily
administration (in principle, MPH-MR08, MPH-MR12,
Methylphenidate prescriptions trend in Germany, 1992 – 2005 Figure 2
Methylphenidate prescriptions trend in Germany, 1992 – 2005. Methylphenidate prescriptions grew 47-fold from 
1992 to 2005. During the same period, total prescriptions in Germany declined by 41 percent. Data source: Wissenschaftliches 
Institut der AOK, Schwabe and Paffrath, 1993 – 2006 [20]; note change of database for year 2001/2002. All data refer to pre-
scriptions reimbursed by statutory health insurance (SHI, "GKV", covering approximately 90 percent of German population); 
excluding parallel imports. Note that these data include prescriptions for adults with ADHD and also for other indications 
(narcolepsy).
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Ritalin SR, and ATX) accounted for 54% of total ADHD-
related prescriptions and 65% of sales in 2005 [19]. These
Prescription Cost Analysis data for England do not
include items dispensed in hospitals.
The high rate of adoption of new products with once-a-
day administration schedules reflects the well-known
problems associated with administration of a mid-day
dose (during school) in children and adolescents with
ADHD [45,46]. Obviously, here a disorder-specific clini-
cal need contributes to the fact that current trends of
ADHD prescribing behavior mirror a more general pattern
encountered in European pharmaceutical markets,
namely, that the diffusion of new products consistently
represents the single most important growth driver [47].
These observations raise the urgent question whether, and
to what extent, pharmaceutical spending for children and
adolescents with ADHD may continue to escalate in the
foreseeable future. It is the purpose of this paper to shed
some light on this issue, using the examples of England
and Germany.
Methods
A forecasting model was developed to project the likely
pharmaceutical expenditures for children and adolescents
(age 6–18 years) with a diagnosis of ADHD in England
and Germany through 2012, specifying assumptions and
assumed relationships between variables in a transparent
manner. Model outcomes were used to estimate the
impact on drug spending by individual German physi-
cians involved in care for ADHD patients, after validation
of the model by replicating historic data (from 1998
Table 1: Treatment options for ADHD in children and adolescents in Germany (D) and the United Kingdom (UK): product availability 
and acquisition cost
Active 
compound Formulation Abbreviation Trade name Manufacturer Authorization1 Cost per treatment day2
UK/D UK D Assumption
Dexamphetamine 
sulphate
Tablets (5 mg) DEX DexedrineR UCB (Celltech) ≤ 2000 £ 0.43 n.a. 20 mg/d
Methylphenidate 
hydrochloride
Immediate-release 
tablets (10 mg)
MPH-IR-o RitalinR UK: Cephalon; D: 
Novartis
≤ 2000 £ 0.56 €1.58 30 mg/d 
(DDD), divided 
in three daily 
doses
Methylphenidate 
hydrochloride
Immediate-release 
tablets (5, 10,
20 mg)
MPH-IR-b Branded 
Generics: 
EquasymRMediki
netR
UCB (previously 
Celltech); Medice 
(D only)
≤ 2000 £ 0.52 €1.41 30 mg/d 
(DDD), divided 
in three daily 
doses
Methylphenidate 
hydrochloride
Immediate-release 
tablets (5, 10,
20 mg)
MPH-IR-g Generics (misc. 
non-
proprietary)
1A, TAD, et al. £ 0.38 €1.13 30 mg/d 
(DDD), divided 
in three daily 
doses
Methylphenidate 
hydrochloride
Modified-release 
tablets (18, 36,
54 mg)
MPH-MR12 ConcertaR XL 
(OROS delivery 
system)
Janssen-Cilag UK: 2002 (Feb., 19) £ 1.23 €2.94 36 mg/d 
(administered 
once daily)
Methylphenidate 
hydrochloride
Modified-release 
capsules (10, 20, 
30, 40 mg)
MPH-MR08
(note different 
formulations)
EquasymR XL 
(biphasic 
Diffucaps 
delivery 
system);
UCB (previously 
Celltech);
UK: 2005 (Feb., 11); 
D: mutual recognition 
May 2006
£ 1.17 30 mg/d 
(administered 
once daily)
MedikinetR 
retard
Medice (D only) D: January 2005 €2.46
Atomoxetine 
hydrochloride
Hard capsules (10, 
18, 25, 40, 60 mg)
ATX StratteraR Eli Lilly UK: 2004 (May, 27);
D: May 2005
£ 1.95
£ 3.80
€3.88
€7.76
(once daily. 
administration)
(administration 
divided in two 
daily doses)
1First authorization in UK, from electronic Medicines Compendium, available online at http://emc.medicines.org.uk, accessed August 12, 2005.
2NHS acquisition costs (not accounting for negotiated procurement discounts in some settings), taken from British National Formulary 51, March 
2006 [75]; note that individual doses and thus costs may vary. German data retrieved from "Gelbe Liste", July 2006 [76]. Note that, at the time of 
printing this paper, in Germany reference prices have been proposed for products containing methylphenidate as the active ingredient.Child and Adolescent Psychiatry and Mental Health 2007, 1:13 http://www.capmh.com/content/1/1/13
Page 6 of 17
(page number not for citation purposes)
Table 2: Data sources and assumptions
(1) Demographic data
Basic demographic data came from national bureaus [77,78]. As a model input, rounded figures of 9.72 million (for Germany, 90% of 10.8 million, 
reflecting population coverage by the GKV) and 8.1 million (England; with the NHS covering the total population) were used for the number of 
persons age 6–18 years. As an estimate of the true prevalence of ADHD, 6% was used for base case analysis (cf. below, scenarios) assuming that 
DSM-IV criteria [79] will be used in clinical practice. A sample of pediatricians surveyed in the German region of Nordbaden [74] had suggested that 
ADHD was diagnosed according these criteria, instead of ICD-10 [80] criteria often referred to in the European literature [81]. The figure of 6% 
came from reviews of epidemiological studies [82,83] that coincided with findings from a German mail survey of 165 parents of children age 6 to 10 
years using a parent rating scale for ADHD [84]. The British Child and Adolescent Mental Health Survey described a prevalence of 2.23% (1999); its 
authors noted that diagnoses might be missed if information is not sought from teachers about children's functioning in school [85].
(2) ADHD diagnosis rates
Information on ADHD recognition rates could be obtained from two regional studies: A claims data analysis using a sample of 35,000 children age 3 to 
15 years covered by a regional sick fund (AOK) in Hessen, Germany, indicated that the administrative prevalence of ADHD increased from 1.24% 
in 1998 to 2.43% in 2001 [86]. In 2003, the administrative prevalence of ADHD among children and adolescents age 7 to 19 years in the German 
region of Nordbaden (N = 317,520) was 2.95% [74]. In line with historic trends up to 2005, it was assumed that awareness of ADHD would 
continue to increase and result in recognition rates going up from approximately 50% (or 3% of the total age group) in 2003 to plateau at 70–80% 
or 4.5% of the population aged 6–18 years from 2010 onwards (for England 65(-70)%, in line with current trends).
(3) ADHD treatment rates
Data on the rate of patients receiving drug therapy (i.e., treatment prevalence) were derived from the regional analyses and tested for consistency 
with top-down estimates based on the number of prescriptions dispensed, revenues booked, and assumed treatment intensity – cf. (6), below. 
These top-down calculations included adjustment for an assumed 5% share of psychostimulant prescriptions for narcolepsy, gradually declining as 
ADHD prescriptions rise. They were also adjusted for an estimated 10% off-label prescriptions for adult patients with ADHD in 2003, as indicated 
by new data from the Nordbaden project [75]. – Analyses of the AOK Hessen sample (for year 2000) revealed a methylphenidate treatment 
prevalence of 0.52% among children and adolescents below age 20 [87]. Of children age 6 to 15 years with a diagnosis of ADHD in the AOK 
Hessen sample, 17% were prescribed methylphenidate in 1998; and this rate increased to 29% in 2000 ([88], p. 32). More recent data from 
Nordbaden indicate that in 2003, 40% (1,161 out of 2,939) of children and adolescents (age group 7–19) with a diagnosis of ADHD were treated 
with stimulant medication [74,89]. For modeling input, these treatment rates were adjusted for regional variation: In 2001, methylphenidate 
prescriptions (defined daily doses, DDDs, per population below age 20) were 17% below the national average in Hessen, while they were 23% 
above the average in Nordbaden [90]. Further it was assumed that the rate of ADHD patients receiving pharmacotherapy would continue to 
increase through 2010 (and remain stable thereafter), reflecting mounting evidence of long-term treatment effectiveness (cf. earlier, Introduction [33-
37]), a growing number of alternative treatment options (cf. below), and the communication efforts by manufacturers competing for market share. 
Model inputs for England were derived from top-down calculations, corrected for prescriptions for adult ADHD patients; regarding narcolepsy, it 
was assumed that this indication would be covered by modafinil (trade name ProvigilR), which has been licensed for the treatment of daytime 
sleepiness associated with narcolepsy or obstructive sleep apnoea [75]. – Note that due to these adjustments model estimates for years 2001 to 
2005 deviate from total market data delineated in the Introduction.
(4) New product profiles and availability
An extensive literature and database search was conducted to obtain information on the expected availability of new products and their likely 
therapeutic profiles. In addition to standard Medline searches, presentations at recent psychiatry and child and adolescent psychiatry congresses in 
the United States and Europe were screened for reports on ADHD treatment. To identify new products on the horizon, further research on drug 
development programs in the field was conducted using the pharmaceutical databases of Scrip World Pharmaceutical News and Therapeutics-Daily 
[49,61]. For key findings, see Results, below, and Table 3. As a rule, it was assumed that new products would become available in Europe (with no 
difference between Germany and England) 18–24 months later than in the United States, reflecting the predominant strategy of pharmaceutical 
companies to choose the United States (currently accounting for more than 90% of global ADHD drug sales) as lead market [49].
(5) Market diffusion rates
Diffusion rates and market shares were modeled separately for each alternative preparation, both by category and by product. Each of the 
quantitative model inputs was informed by findings of the literature and database review (cf. above, 4, and Results, below), and supported by expert 
consensus derived from semi-structured interviews with experienced pharmaceutical market specialists. For immediate-release preparations of 
methylphenidate (MPH-IR), generic market penetration was assumed to reach 70–75% towards the end of the projection period (branded MPH-IR, 
RitalinR, 10%, and dexmethylphenidate, FocalinR, 20% – cf. also Results); this applied similarly to the projections for England and Germany.
(6) Treatment intensity
Treatment intensity was expressed by a single index representing the average number of days on treatment with one defined daily dose (DDD) per 
day. (For atomoxetine, in a certain number of patients twice daily dosing may be required [91,92]; this was assumed to be the case in 20% of 
patients on this drug.) On the basis of a methylphenidate (MPH-IR) prescribing analysis in the German region of Hessen, it was estimated that the 
median duration of treatment had been about 120 days in 2000 [87]. This figure may underestimate the actual duration of treatment since no 
adjustment for data edge effects was made in this study. Treatment persistence with modified-release products should be higher owing to improved 
treatment compliance. This expectation has received support from two independent Medicaid claims data studies from California and Texas that 
found a 37% increase in uninterrupted duration of initial MPH-MR treatment compared to MPH-IR [93,94]. Between 2000 and 2003, mean duration 
of ADHD treatment was 158 days with MPH-MR and 128 days with MPH-IR [93]. It was further assumed for some scenarios (cf. below, Table 3) 
that average treatment intensity would tend to increase reflecting findings of the NIMH MTA study [35-37].
(7) Product acquisition costs
Acquisition costs per defined daily dose were calculated for each product from the perspectives of the NHS (England) or the GKV (Germany), 
respectively. For marketed products, data for large pack sizes (Germany: N2, typically containing 28 to 30 single doses) were retrieved for March 
2006 (England) or July 2006 (Germany) from standard sources [75,76]. Ex-pharmacy prices were not corrected for co-payments since the vast 
majority of patients age 18 years or younger have been exempt from cost-sharing in both England and Germany. It was generally assumed that there 
would be no price increases during the projection period. Pricing assumptions for new products are described below (cf. also Tables 1 and 3).Child and Adolescent Psychiatry and Mental Health 2007, 1:13 http://www.capmh.com/content/1/1/13
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to 2005). Key uncertainties were addressed using scenario
analysis, combining objective information with specific
assumptions about future events [48].
The model was restricted to pharmaceutical spending. It
combined, in a hierarchical structure, (1) epidemiological
information (demographic and prevalence data) with
assumptions on (2) recognition rates (diagnosis preva-
lence), (3) rate of patients receiving drug therapy (treat-
ment prevalence), (4) availability and adoption of new
products, incorporating information on therapeutic pro-
files, (5) diffusion and market shares for alternative prep-
arations, by category and by product, including generic
substitution, (6) treatment intensity (expressed as average
number of days times defined daily doses), (7) acquisi-
tion cost per defined daily dose for each product, from the
perspectives of the NHS (England) or the GKV (Ger-
many), respectively. For validation of the model, available
data on the variables above were used to compare model
outcomes with the historic evolution of drug spending in
England and Germany. Extensions of the model were used
to estimate the impact of the projections on drug budgets
of individual pediatricians and specialists in child and
adolescent psychiatry participating in care for patients
w i t h  A D H D  i n  G e r m a n y .  D e t a i l s  o n  d a t a  s o u r c e s  a n d
assumptions are provided in Table 2.
Results
1. New products in development (and further assumptions)
The market for ADHD treatment has attracted pharmaceu-
tical companies to invest heavily in new product develop-
ment. Results of literature searches and the database
analysis [49] are summarized in Table 3.
A number of further pharmaceutical preparations and var-
iants of methylphenidate are in phase III of clinical devel-
opment in Europe, some of which have already received
marketing authorization in the United States. These
include a transdermal system (TDS, approved as Daytra-
naR in the United States, April 2006) of methylphenidate
with duration of action of 12 hours (wear time, 9 hours).
At present, in the absence of head-to-head trials against
established oral formulations, the main advantage of this
product seems to be convenience-related [49-51]. For
modeling, it has therefore been assumed that it would
capture no more than 10% of methylphenidate prescrip-
tions. This implies the expectation that there will be no
significant problems associated with skin sensitization.
Dexmethylphenidate, the chirally pure active isomer of
methylphenidate, has been licensed as FocalinR
(Novartis) in the US in May 2005, also as an extended-
release formulation [49,52]. As there is currently no evi-
dence of superiority in terms of efficacy or tolerability
[49,53], it has been assumed that FocalinR will become
available in Europe without a price premium over
branded immediate-release (RitalinR, also Novartis) or
modified-release methylphenidate (ConcertaR, Janssen-
Cilag), respectively. Given its investment in FocalinR, it
has been considered unlikely that Novartis would launch
RitalinR LA (a long-acting preparation of methylphenidate
available in the United States and some other markets) in
England and Germany.
At the time of writing, few scientific data were in the pub-
lic domain about lisdexamphetamine mesylate
(NRP104), a new chemical entity that is an inactive prod-
rug of amphetamine believed to have a reduced potential
for abuse and overdose compared to other ADHD drugs.
The reason is that the amphetamine is conjugated to a spe-
cific amino acid and is activated only when metabolized
in the gastrointestinal tract. Shire filed the product with
the Food and Drug Administration (FDA) in December
2005 for the treatment of ADHD in children aged 6 to 12.
Phase III study results presented at the Annual Meeting of
the American Psychiatric Association in Toronto, May
2006, indicated similar efficacy and tolerability compared
to mixed amphetamine salts (AdderallR) and duration of
action of 12 hours [49]. A preliminary review of NRP104
by the U.S. Drug Enforcement Administration indicated
(8) Prescribing patterns
Data indicating physician-specific prescription patterns were available for Germany only. At the same time, such data may be most relevant to German 
physicians, since they are subject to individual drug budget regulation, which differs from the system of Primary Care Groups in England [95]. 
Pediatricians treated most (5,605 of 11,245 below age 20 years, or 50%) of these patients in Nordbaden (2003), followed by child# and adolescent 
psychiatrists (3,369 or 30%) [74]. For comparison, in the smaller Hessen sample from 1998–2000, pediatricians accounted for 44% of 
methylphenidate prescriptions in 2000 [90]. Within physician groups, care for patients with ADHD was highly concentrated in Nordbaden: the top-
50% of child and adolescent psychiatrists accounted for 92.1% of ADHD patients treated by their group, and the top-20% of pediatricians accounted 
for a share of 66.2%. Since budgetary impact of ADHD medications will be of relevance only to those physicians involved in care for these patients, 
the average impact was determined for the top-50% of child and adolescent psychiatrists and the top-20% of pediatricians, respectively. Total 
prescription drug spending caused by pediatricians (including drugs for ADHD) was €92,000 per physician in 2004 (2002: €83,000) [20]. Total drug 
spending of each of the top-50% child and adolescent psychiatrists was estimated at €51,000 in 2004, assuming that 76% of their psychotropic drug 
expenditures in this year were due to ADHD treatment, derived from data on psychotropic prescriptions for children age 15 or younger [20]. This 
estimate was consistent with prescribing data obtained from Nordbaden [96], when allowing for regional variance described above. Further 
assuming non-ADHD expenditures to grow at an annual rate of 5%, the impact of projected future ADHD spending on individual physicians could 
be estimated.
Table 2: Data sources and assumptions (Continued)Child and Adolescent Psychiatry and Mental Health 2007, 1:13 http://www.capmh.com/content/1/1/13
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that the compound would not be subject to controlled-
substance scheduling [54], although this initial judgment
has been revised since. The compound was launched by
Shire in the United States end of July 2007 under the trade
name "VyvanseR". For modeling it was assumed that the
product will be introduced to the English and German
markets in 2008 and (except for the "Extremely Low Case"
scenario) overtake modified-release methylphenidate
products in terms of prescriptions by 2012. Obviously,
this rests on the assumption that clinical advantages of
NRP104 (regarding abuse potential, possibly tolerability
profile, as well as label and summary of product character-
istics) will be confirmed.
Modafinil has been licensed as "ProvigilR" as a wake-pro-
moting agent for patients with narcolepsy and shift work
sleep disorder in the United States and England. Its
manufacturer, Cephalon, has reformulated modafinil for
children as once-daily 85 mg film-coated tablets, which it
claims to be smaller and easier to swallow. Of note, this
change of formulation should protect the new indication
from generic competition [49]. While its mechanism of
action is not fully understood, modafinil is classified as
nonstimulant [55-57]. Similar to atomoxetine [58], a
selective norepinephrine reuptake inhibitor, improve-
ment of core symptoms had an effect size on core symp-
toms (school version of ADHD-RS) of 0.69 [59] to 0.76
[60]. This compares to effect sizes around 1.0 typically
achieved with stimulants [58]. In August 2006, Cephalon
announced discontinuation of modafinil development
for ADHD due to safety concerns raised by the FDA, and
the company intends to replace modafinil by its successor
compound in development, armodafinil [61]. It has been
assumed for modeling that armodafinil (like atomoxetine
Table 3: New products in development for treatment of ADHD in children and adolescents: overview of compounds not yet available 
in England and Germany
Active ingredient
Abbreviation/
Pharmaceutical 
preparation Trade name (US) Manufacturer
Approval status 
(US) Notes
Methylphenidate 
hydrochloride
MPH-MR08 
(modified-release 
preparation)
RitalinR LA (using 
SODAS delivery 
system developed by 
Elan)
Novartis available in US and 
Switzerland
Methylphenidate 
hydrochloride
MPH-TDS Patch for 
transdermal drug 
delivery (o.a.d); 12 h 
duration of action
DaytranaR DOT 
matrix transdermal 
technology
Shire (in license from 
Noven)
US approval (children 
age 6–12 years) April 
2006; 2nd line to oral 
drugs
Skin sensitization 
reported in 13–22% of 
subjects wearing the 
patch; product had 
been deemed non-
approvable by FDA 
before (April 2003)
Dexmethylphenidate, 
a non-racemic form of 
methylphenidate:
d-MPH (the active 
isomer of 
methylphenidate)
FocalinR Novartis (in license 
from Celgene)
Approved in US
Dexmethylphenidate, 
a non-racemic form of 
methylphenidate:
d-MPH-ER (extended 
release formulation)
FocalinR XR Novartis (in license 
from Celgene)
US approval (for 
"children, adolescents, 
and adults") May 2005
Lisdexamphetamine 
dimesylate
LisDEX; 
(pharmaceutical 
preparation with a 
o.a.d. dosing schedule)
NRP104 Shire (in license from 
New River 
Pharmaceuticals)
US approval (for 
children age 6–12 
years) granted in 2007
Reduced abuse 
potential expected 
because amphetamine 
is linked to L-lysine 
and does no become 
active until 
metabolized in the 
gastrointestinal tract
Mixed amphetamine 
salts
MAS (immediate and 
extended release 
formulations
AdderallR, AdderallR 
XR
Shire Available in US Unlikely to be 
approved in Europe
Modafinil
Successor compound: 
Armodafinil
MOD; dopamine 
reuptake inhibitor; 
effects on 
neuropetides possible
ARM
SparlonR (licensed in 
US and UK as 
ProvigilR for 
narcolepsy)
NuvigilR
Cephalon
(SparlonR was planned 
to be co-promoted in 
the US by McNeil, a 
sister company of 
Janssen-Cilag)
After receiving a non-
approvable letter for 
modafinil in ADHD 
from the FDA in 
August 2006, 
Cephalon refocused 
its R&D on 
armodafinil [61]
Suspected serious 
adverse events (skin 
rash/Stevens-Johnson 
syndrome) in 
association with 
modafinil
Only projects in phase III of clinical development or products already marketed in the United States. DaytranaR was formerly known as 
"MethypatchR", SparlonR as "AttenaceR". Data source: InnoVal-HC, 2006 [49].Child and Adolescent Psychiatry and Mental Health 2007, 1:13 http://www.capmh.com/content/1/1/13
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[62,63]) would become a second line treatment option
after stimulants.
Finally, mixed amphetamine salts are marketed success-
fully in the U.S. (AdderallR, AdderallR XR, by Shire) but
have been licensed neither in England nor in Germany. It
is believed that these products will not become available
in Europe. Further compounds in phase II clinical devel-
opment for ADHD include selective GABA-B receptor
antagonists (SGS742, by Saegis, a privately held company
with Novartis among its investors) and ampakine mole-
cules (by Cortex). These projects have been excluded from
the present study in light of their inherent uncertainty; sta-
tistically, attrition rates of compounds in clinical phase II
are as high as 62% [64].
2. Projected budgetary impact from the perspectives of the 
German Statutory Health Insurance (SHI, GKV) and the 
National Health Service (NHS) in England
First, the model was calibrated using data on ADHD-
related prescriptions and expenditures from 1998 to 2005
(cf. above). Besides a base case for projection through
2012 (Figure 3), four additional scenarios were defined to
address the uncertainty surrounding critical assumptions
(for details, see above and Table 4). Two scenarios (upper
and lower bounds of base case) represented plausible var-
iants, assuming different rates of treatment prevalence
and intensity. Two further scenarios reflected extremes,
the lower one assuming no price premiums for the new
products and low treatment intensity, while the high
Table 4: Key assumptions underlying scenarios (base case and extreme cases)
Key assumptions1 Low Case (Extreme) Base Case (Projection) High Case (Extreme)
Adjustments (all scenarios) Germany: narcolepsy 2% of prescriptions in 2003; adult ADHD accounts for 10% of prescriptions in 2003
England: ProvigilR prescriptions cover narcolepsy exhaustively, no off-label use of modafinil for ADHD; 
modafinil for ADHD will be priced at the same level as ProvigilR; adult ADHD accounts for 10% of 
prescriptions in 2003
Peak diagnosis prevalence England: 3.90%
Germany: 4.20%
England: 3.90%
Germany: 4.50%
England: 4.20%
Germany: 4.80%
Peak treatment prevalence England: 2.54%
Germany: 3.15%
England: 2.54%
Germany: 3.38%
England: 2.94%
Germany: 3.84%
New product availability dMPH (FocalinR) 2007;
MPH-TDS 2008;
LisDEX 2008;
ARM/MOD ./.
dMPH (FocalinR) 2007;
MPH-TDS 2008;
LisDEX 2008;
ARM/MOD 2009
New products, specific notes ARM/MOD not approved;
LisDEX without clinical advantage 
over MPH-MR;
dMPH (IR/MR) profile comparable 
to MPH-IR and MPH-MR08, 
respectively;
MPH-TDS advantage limited to 
"convenience", no sensitization 
problems
ARM/MOD comparable to ATX;
LisDEX: reduced abuse and 
diversion potential shown;
dMPH (FocalinR) profile 
comparable to MPH-IR (dMPH-IR) 
and MPH-MR08 (dMPH-MR), 
respectively;
MPH-TDS advantage limited to 
"convenience", no sensitization 
problems
ARM comparable to ATX;
LisDEX: non-scheduled for 
reduced abuse potential;
dMPH (FocalinR) profile 
comparable to MPH-IR and MPH-
MR08, respectively;
MPH-TDS advantage limited to 
"convenience", no sensitization 
problems
New product pricing FocalinR = branded MPH-IR;
FocalinR XR = MPH-MR12;
LisDEX and MPH-TDS 50% 
premium over MPH-MR12;
ARM/MOD n.a.
Price of dMPH-IR (FocalinR) = 
branded MPH-IR;
dMPH-MR (FocalinR XR) = MPH-
MR12;
LisDEX and MPH-TDS 50% price 
premium over MPH-MR12;
ARM/MOD = ATX (20% b.i.d.) in 
Germany;
ARM/MOD for ADHD in England 
priced like ProvigilR.
FocalinR = branded MPH-IR;
FocalinR XR = MPH-MR12;
LisDEX and MPH-TDS 100% 
premium over MPH-MR12;
ARM/MOD = LisDEX (D)
Established products No price increases (except for DEX in England in "Extremely High Case" scenario).
Generic MPH-IR market up to 90% (Germany) or 95% (England), respectively; FocalinR up to 20% of MPH-IR 
market share.
No generic substitution for ATX or MPH-MR market segments.
ATX administered b.i.d. in 20% of patients.
Treatment intensity No change compared to 2005 
(current trend ends 2006)
Continuation of current trend, 
phasing out by 2010
Continuation of current trend, 
phasing out by 2012
1Abbreviations: MPH: methylphenidate; IR: immediate-release formulations (RitalinR, branded generics [EquasymR, MedikinetR], generics; FocalinR); 
MR: modified-release formulations (MPH-MR12: ConcertaR XL; MPH-MR08: EquasymR XL, MedikinetR retard, FocalinR XR; MPH-TDS: transdermal 
system (patch, DaytranaR); LisDEX: lisdexamphetamine (NRP104); Nonstimulants: ATX, atomoxetine (StratteraR), ARM, armodafinil (NuvigilR); 
DEX: dexamphetamine (England only)Child and Adolescent Psychiatry and Mental Health 2007, 1:13 http://www.capmh.com/content/1/1/13
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extreme combined the effects of intense treatment with
higher price premiums for new products.
While all scenarios will be described briefly below, Tables
4 and 5 have been limited to a more detailed account of
the base case and the extreme scenarios. Interested readers
may retrieve the full details from our Institute's
website [97].
The base case scenario, which is believed to reflect the
most probable course of future events, implies an increase
of drug spending for children and adolescents with
ADHD for year 2012 by a factor of 12 (GKV in Germany)
or 10 (NHS in England) over 2002. Assuming an annual
growth rate of 5% for drug expenditures between 2005
and 2012 (except for ADHD in children and adolescents),
then the projected ADHD treatment costs (from the NHS
perspective, £78 million) would make up 3.8% of NHS
spending for CNS drugs in 2012, compared to just 0.77%
in 2002. For the German GKV (projected spending,  311
million), the corresponding figures would be 12.9% of
total spending for psychotropic drugs in 2012, compared
to 1.8% in 2002. This increase is driven by the multiplica-
tive effects of increasing awareness and recognition of
ADHD, growing rates of pharmacotherapy, somewhat
increased intensity (dose and duration) of treatment, and
the shift to novel, more expensive products (cf. Figure 3).
The upper and lower bounds of the base case can be inter-
preted as sensitivity analyses with regard to treatment
intensity; these indicate a plausible range of spending esti-
mates from  259 to  380 million in Germany and from
£63 to £101 million in England in 2012. The differences
between both jurisdictions reflect the effects of differences
in population size, unit costs, available products, and a
lower baseline and less dynamic increase in England com-
pared to Germany.
Projected prescription drug expenditures for ADHD in children and adolescents, 2001 – 2012 (base case) Figure 3
Projected prescription drug expenditures for ADHD in children and adolescents, 2001 – 2012 (base case). a, b: 
Defined daily doses (DDDs) p.a.; c, d: expenditures by category p.a.; e, f: total (cumulated) expenditures p.a.; left: England; right: 
Germany. MPH: methylphenidate; IR: immediate-release formulations (RitalinR, branded generics [EquasymR, MedikinetR], 
generics; FocalinR); MR: modified-release formulations (ConcertaR XL, EquasymR XL, MedikinetR retard, FocalinR XR; MPH-
Patch: transdermal system (DaytranaR); LisDEX: lisdexamphetamine (NRP104); Nonstimulants: atomoxetine (StratteraR), 
armodafinil (NuvigilR); DEX: dexamphetamine (England only).
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The extremely high scenario indicates the sensitivity of
projections to higher prices of new products (cf. Tables 4
and 5). Additional scenarios were computed and fell
within the range indicated. Of note, a scenario with much
less successful lisdexamphetamine (assuming no advan-
tage over modified-release methylphenidate) produced a
spending projection of  249 million or £67 million in
2012, roughly corresponding to the lower bound of the
base case (Figure 4). An extremely low case was calculated
resting on very conservative assumptions (cf. Tables 4
and 5) regarding diagnosis and treatment prevalence
rates, absence of any further increase in treatment inten-
sity, a disappointing clinical profile and subsequent low
adoption rate of lisdexamphetamine, and denial of mar-
ket access for modafinil and armodafinil. This led to an
estimated spending of  170 m or £49 million in 2012,
still an increase over 2002 by a factor >6 for both Ger-
many and England (Figure 4).
3. Impact on individual physicians
These projections have been related to individual German
physicians involved in care for children and adolescents
with ADHD. Since ADHD care is a highly concentrated
phenomenon (cf. Table 2), average spending (again, from
the perspective of the GKV) for ADHD pharmacotherapy
was calculated for the top-50% of child and adolescent
psychiatrists, and the top-20% of pediatricians (see
Figure 5).
Under base case assumptions, total annual drug spending
of these child and adolescent psychiatrists would grow
from an average total of less than  30,000 per physician
in 2002 to  282,000 in 2012, of which  264,000 would
be caused by prescriptions for ADHD treatment in chil-
dren and adolescents (Figure 5). (Of course, as adult
patients with ADHD have not been included in this anal-
ysis, the total budgetary impact of ADHD may be greater
for those specialists who also treat adults, for example par-
ents of patients.) This almost tenfold increase is the result
of (a) the projected ADHD spending in combination with
(b) the high concentration of patients among a small total
number of specialists and (c) the very small number of
prescriptions traditionally written by this specialist group.
Even for the extremely low case looked at, this overall
increase of drug spending by individual physicians would
result in >5-fold drug spending caused by these specialists
in 2012, compared to 2002. In this most conservative
scenario,  144,500 or 89% of projected expenditures
of 162,600 per physician in 2012 would still be
accounted for by young ADHD patients.
Pediatricians as a group cause higher drug expenditures,
and each of them treats a smaller number of ADHD
patients compared to specialists, even those who are
among the top-20% service providers for children with
ADHD among their group. Hence, the incremental impact
of ADHD-related spending is smaller compared to child
Table 5: Projected expenditures by scenario: ADHD pharmacotherapy for children and adolescents in England and Germany, 2012
Key projections1 England Germany
Scenario Low Extreme Base Case High Extreme Low Extreme Base Case High Extreme
Expenditures 
2012
49 m£ 78 m£ 117 m£ 170 m€ 311 m€ 456 m€
Increase 2012 
over 2002
+602% +1,012% +1,561% +617% +1,210% +1,825%
Total CNS2 
market (2012)
2,039 m£(1,463 
m£)
2,068 m£ (1,492 
m£)
2,107 m£(1,531 
m£)
2,261 m€(1,585 
m€)
2,402 m€ (1,726 
m€)
2,547 m€(1,871 
m€)
Share of total2 
market (2012)
2.4% (3.4%) 3.8% (5.2%) 5.5% (7.6%) 7.5% (10.7%) 12.9% (18.0%) 17.9% (24.4%)
Projections by 
products
Stimulants 40.7 m£ 58.3 m£ 91.3 m£ 141 m€ 259 m€ 390 m€
DEX 0.6 m£ 0.7 m£ 1.2 m£ n.a. n.a.n . a .
MPH-IR 1.2 m£ 1.5 m£ 1.9 m£ 5 m€ 7 m€ 8 m€
MPH-MR 22.3 m£ 18.4 m£ 24.4 m£ 90 m€ 74 m€ 92 m€
MPH-TDS 6.7 m£ 8.4 m£ 14.2 m£ 24 m€ 36 m€ 58 m€
LisDEX 10 m£ 29.2 m£ 49.6 m£ 22 m€ 143 m€ 232 m€
Nonstimulants 8.6 m£ 20.0 m£ 25.5 m£ 29 m€ 51 m€ 67 m€
ATX 8.6 m£ 10.7 m£ 13.7 m£ 29 m€ 39 m€ 47 m€
ARM n.a. 9.2 m£ 11.8 m£ n.a. 13 m€ 20 m€
1For abbreviations, see legend to Table 4. 2(share of) market for psychotropics (D) or CNS drugs (UK), calculated assuming a growth rate of 5% p.a. 
(figures in brackets represent one of the sensitivity analyses, indicating market shares assuming no growth of non-ADHD market segment); for 
comparison: share of market segment in 2002 was 0.77% (NHS, England) and 1.8% (GKV, Germany), respectively.Child and Adolescent Psychiatry and Mental Health 2007, 1:13 http://www.capmh.com/content/1/1/13
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and adolescent psychiatrists (Figure 4). Still, under base
case conditions, ADHD-related pharmaceutical expendi-
tures would account for 39% (or  75,000 out of  193,000
per physician in 2012, assuming a 5% growth rate of non-
ADHD pharmaceutical spending) of total drug costs
induced by this group. These figures compare with average
drug costs of  83,000 per pediatrician in 2002. Thus,
ADHD-related prescriptions alone would account for two
thirds of the growth in drug expenditures caused by these
physicians between 2002 and 2012.
Discussion and limitations
Without exception, all plausible scenarios for England
and Germany point to a further increase of expenditures
for ADHD medication. The striking extent of the projected
increase may appear counterintuitive, but it is easily
explained by the simultaneous and multiplicative effects
exerted by four variables, i.e., increases in diagnosis
prevalence, treatment prevalence, treatment intensity, and
the shift to more expensive new products. Over a wide
range of assumptions, all projections concur indicating a
strong impact of this increase on the individual drug
budgets of physicians treating patients with ADHD.
Some important limitations of the present analysis war-
rant discussion. First, the present analysis does not pur-
port to convey value judgments. It has little to nothing to
say about the clinical appropriateness of the prescriptions
analyzed; its mere focus is on their budgetary impact.
Second, there is substantial uncertainty around future
events. Compounds in development may be discontin-
ued, marketed drugs may be withdrawn because of serious
adverse events, safety concerns may slow down diffusion
of new products, and so on. The dynamic health policy
environment is yet another factor. However, it would
Range of plausible projections: expenditures under extreme case scenarios, 2001–2012 Figure 4
Range of plausible projections: expenditures under extreme case scenarios, 2001–2012. a, b: "High Extreme" Case; 
c, d: Base Case modified "LisDEX without clinical advantage over MPH-MR"; e, f: "Low Extreme" Case; left: England; right: Ger-
many. MPH: methylphenidate; IR: immediate-release formulations (RitalinR, branded generics [EquasymR, MedikinetR], generics; 
FocalinR); MR: modified-release formulations (ConcertaR XL, EquasymR XL, MedikinetR retard, FocalinR XR; MPH-Patch: 
transdermal system (DaytranaR); LisDEX: lisdexamphetamine (NRP104); Nonstimulants: ATX, atomoxetine (StratteraR), ARM, 
armodafinil (SparlonR); DEX: dexamphetamine (England only).
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hardly be a prudent response to uncertainty to abandon
planning and taking a proactive role in the pursuit of effi-
cient service provision.
In strategic management, scenario analysis is a well-
established tool to deal with environmental uncertainty
[65]. The practice of scenario planning implicitly
acknowledges that "best guesses" of future events may be
wrong. Therefore, any scenario should not be confused
with a forecast of the future. Multiple scenarios are pen-
pictures of a range of plausible futures (Figures 3 and 4).
Though each individual scenario has an infinitesimal
probability of actual occurrence, combined a range of sce-
narios can shed light on possible future outcomes. This in
Projected impact of ADHD treatment for children and adolescents on individual physicians' prescription drug expenditures,  2001–2012 (base case) Figure 5
Projected impact of ADHD treatment for children and adolescents on individual physicians' prescription drug 
expenditures, 2001–2012 (base case). a: Child and adolescent psychiatrists; b: pediatricians in private practice in Germany. 
Expenditures expressed as €/physician and year; perspective of statutory health insurance (i.e., excluding privately health 
insured patients). Data represent average values for one of the upper 50% of child and adolescent psychiatrists and one of the 
upper 20% of pediatricians in terms of relative involvement in care for ADHD patients, respectively. Concentration of care 
modeled according to Nordbaden data [74]. Abbreviation: Non-ADHD-Rx: expenditures for treatment of conditions other 
than ADHD.
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turn should enable to plan for the range of futures that
could, plausibly, unfold.
A third important limitation of this study concerns its
restricted scope. Although pharmaceutical spending is
likely to rise faster than other ADHD-related expenditures,
it is certainly not the only cost component to be consid-
ered in a complete budgetary impact analysis [30,66].
Even more importantly, cost analyses illuminate just one
half of the health economic equation; they do not provide
information on "value for money", frequently analyzed in
terms of cost-effectiveness [67]. Cost-effectiveness analy-
ses of ADHD treatment strategies, however, have been rare
[68], are only now beginning to appear [69-71], and have
generally been limited to a one-year time horizon [72].
Implications
In combination, the scenarios developed here strongly
suggest that the trend of rising drug expenditures for
ADHD may not abate in the near future (Figure 3).
They further indicate that physicians involved in provid-
ing care for children and adolescents with ADHD should
anticipate escalating expenditures and challenging ques-
tions from payers (Figure 5). In particular for German
child and adolescent psychiatrists, as well as for pediatri-
cians in private practice, there will be a growing need to
demonstrate appropriate prescribing practices and the
achievement of clinical benefits commensurate with lev-
els of spending.
Likewise, pharmaceutical manufacturers developing and
selling products for the treatment of patients with ADHD
will need to produce timely evidence supporting the eco-
nomic value of their products.
Finally, it should be noted that the present study was lim-
ited to ADHD in children and adolescents age 6 to 18
years. There is reason to assume that adult ADHD may be
associated with substantial spending dynamics, which has
only just begun to show [73]. This fact, however, lends
further support to the key conclusion of the present study,
namely, that there will be a rapidly growing need for
health economic evidence on the value of clinical inter-
ventions for ADHD.
Abbreviations
ARM – armodafinil
ATX – atomoxetine
DEX – dexamphetamine
dMPH – dexmethylphenidate
FDA – Food and Drug Administration, the United States
regulatory agency deciding on marketing authorizations
for pharmaceutical products
GKV – Gesetzliche Krankenversicherung, statutory health
insurance in Germany, covering approximately 90% of
the population
IR – immediate release (formulation)
LisDEX – lisdexamphetamine, a prodrug of amphetamine
in phase III clinical development
MAS – mixed amphetamine salts
MOD – modafinil
MPH – methylphenidate
MR – modified release (formulation)
MR08 – modified release formulation with duration of
action of approximately 8 hours
MR12 – modified release formulation with duration of
action of approximately 12 hours
NHS – National Health Service (England)
SHI – statutory health insurance in Germany (see GKV)
TDS – transdermal system
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